Matthew Wagar, MD, discusses the addition of T-DXd to the HER2-positive endometrial cancer treatment paradigm.
Matthew Wagar, MD
Advertisement
Matthew Wagar, MD, is a gynecologic oncology fellow in the Department of Obstetrics and Gynecology at the University of Wisconsin School of Medicine and Public Health.
Articles by Matthew Wagar, MD
Matthew Wagar, MD, discusses how the management of advanced and recurrent endometrial cancer has evolved in recent years.
Matthew Wagar, MD, discusses lenvatinib plus pembrolizumab vs chemotherapy as first-line treatment for advanced endometrial cancer.
Matthew Wagar, MD, discusses the use of adjuvant immunotherapy in endometrial cancer and the importance of accurate staging in optimizing outcomes.
Advertisement
Latest Updated Articles
Dr Wagar on the Evolution of Advanced/Recurrent Endometrial Cancer ManagementPublished: March 12th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
5